ALLMedicine™ Essential Tremor Center

May 13th, 2022 - Spasmodic dysphonia (SD) is a focal dystonia affecting the neural control of the laryngeal musculature for speech production. Although the clinical symptoms of SD have been described, the underlying pathological mechanisms remain unknown. Treatmen...

May 11th, 2022 - In patients with essential tremor (ET) treated with standard deep brain stimulation (sDBS) whose ET had progressed and who no longer received optimal benefit from sDBS, directional deep brain stimulation (dDBS) may provide better tremor control. C...

May 11th, 2022 - Essential Tremor (ET) is the most common movement disorder. It is estimated that between 25 and 55% of patients with ET will have a tremor which is refractory to pharmacotherapy necessitating advanced therapeutic options to control tremor. Deep Br...

May 10th, 2022 - Essential tremor (ET) is one of the most common movement disorders worldwide, yet the size of the pediatric ET population is not well understood. The objective of this review was to identify, evaluate, and synthesize evidence describing the epidem...

May 5th, 2022 - This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.

May 13th, 2022 - Spasmodic dysphonia (SD) is a focal dystonia affecting the neural control of the laryngeal musculature for speech production. Although the clinical symptoms of SD have been described, the underlying pathological mechanisms remain unknown. Treatmen...

May 11th, 2022 - Essential Tremor (ET) is the most common movement disorder. It is estimated that between 25 and 55% of patients with ET will have a tremor which is refractory to pharmacotherapy necessitating advanced therapeutic options to control tremor. Deep Br...

May 5th, 2022 - This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.

Apr 22nd, 2022 - Movement disorders are a prominent cause of disability worldwide. In the United States, it is estimated that more than 4 million people suffer from Parkinson's disease (PD), essential tremor (ET), and dystonia, some of the most prevalent of neurol...

Apr 12th, 2022 - Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named [18F] LBT-999 in brain imaging compared to the SPECT reference method named [123I]-FP-CIT to establish the differential diagn...

Jan 13th, 2022 - Several common regions of DNA are linked to an increased risk of developing essential tremor (ET), new research shows. Investigators studied more than 480,000 adults and found five genetic loci that were significantly associated with ET risk, part...

Sep 27th, 2021 - The investigational oral, neuroactive, steroid-positive allosteric modulator SAGE-324/BIIB124 (SAGE-324) is effective for treating essential tremor ― but problems with tolerability may limit its usefulness, new research suggests. The phase 2 KINET...

Aug 30th, 2021 - A new noninvasive procedure is safe and effective for treating patients with mild Alzheimer's disease (AD), new research suggests. Clinicians monitor a trial patient with AD undergoing low-intensity focused ultrasound. The approach uses MRI-guided...

Jun 8th, 2021 - The US Food and Drug Administration (FDA) has approved Medtronic's technologically advanced deep brain stimulation (DBS) system designed to more precisely target motor symptoms in Parkinson's disease, dystonia, or essential tremor. The SenSight Di...

Jan 5th, 2021 - Mark Steven Wallace, MD Many have put forth medical cannabis as a promising treatment for chronic pain that can potentially replace opioids. However, although it's never been easier for patients to access medical cannabis, those researching its us...